Akcea Therapeutics Announces Completion of Enrollment in Phase 3 COMPASS Trial of Volanesorsen

Study designed to support regulatory filings in U.S., E.U. and Canada for volanesorsen CAMBRIDGE, Mass., May 16, 2016 /PRNewswire/ -- Akcea Therapeutics, a subsidiary of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) focused on developing and commercializing innovative treatments for serious cardiometabolic diseases, today announced the completion of enrollment in the COMPASS study, a randomized, double-blind, placebo-controlled, Phase 3 study of volanesorsen in patients with severe hypertriglyceridemia.

The release as fetched from its publisher. ionis.com ↗